Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.
Antibody-dependent cell cytotoxicity
Natural Killer cell
microfluidics
organotypic model
solid tumor
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
30
08
2018
revised:
06
11
2018
accepted:
14
11
2018
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
7
2
2019
Statut:
epublish
Résumé
Immunotherapies against solid tumors face additional challenges compared with hematological cancers. In solid tumors, immune cells and antibodies need to extravasate from vasculature, find the tumor, and migrate through a dense mass of cells. These multiple steps pose significant obstacles for solid tumor immunotherapy and their study has remained difficult using classic
Identifiants
pubmed: 30723584
doi: 10.1080/2162402X.2018.1553477
pii: 1553477
pmc: PMC6350694
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1553477Subventions
Organisme : NCI NIH HHS
ID : R01 CA185747
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205101
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211082
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197078
Pays : United States
Références
J Immunol. 2003 Sep 15;171(6):2889-95
pubmed: 12960311
Mol Immunol. 2005 Feb;42(4):541-6
pubmed: 15607811
Exp Hematol. 2005 Feb;33(2):159-64
pubmed: 15676209
Drug News Perspect. 2007 Apr;20(3):155-63
pubmed: 17520092
J Immunol. 2008 May 1;180(9):6392-401
pubmed: 18424763
Cytotherapy. 2008;10(6):625-32
pubmed: 18836917
Science. 2010 Jun 25;328(5986):1662-8
pubmed: 20576885
Leuk Lymphoma. 2012 May;53(5):958-65
pubmed: 22023526
Lab Chip. 2012 Apr 7;12(7):1224-37
pubmed: 22318426
Immunotherapy. 2012 May;4(5):511-27
pubmed: 22642334
Int J Oncol. 2012 Dec;41(6):2005-12
pubmed: 22992985
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Eur J Immunol. 2013 Oct;43(10):2756-64
pubmed: 23913266
Protein Eng Des Sel. 2013 Oct;26(10):561-9
pubmed: 24025193
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19402-7
pubmed: 24218566
Nature. 2014 Mar 13;507(7491):181-9
pubmed: 24622198
Cancer Discov. 2014 May;4(5):522-6
pubmed: 24795012
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Cancer Res. 2014 Oct 15;74(20):5746-57
pubmed: 25164008
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):214-9
pubmed: 25524628
Oncotarget. 2015 May 30;6(15):13835-43
pubmed: 26079948
Front Immunol. 2015 Jun 10;6:266
pubmed: 26113846
Lab Chip. 2015 Aug 7;15(15):3222-31
pubmed: 26126574
Front Immunol. 2015 Jul 27;6:368
pubmed: 26284063
Front Immunol. 2015 Sep 23;6:482
pubmed: 26441986
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14467-72
pubmed: 26598681
Adv Healthc Mater. 2016 Jan 21;5(2):198-204
pubmed: 26610188
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Drug Discov Today. 2016 Sep;21(9):1472-1478
pubmed: 27185084
Sci Rep. 2016 Aug 23;6:31589
pubmed: 27549930
J Immunol Res. 2017;2017:5210459
pubmed: 28116322
J Hematol Oncol. 2017 Apr 24;10(1):94
pubmed: 28434396
JCI Insight. 2017 Jun 15;2(12):null
pubmed: 28614795
Tissue Eng Part C Methods. 2017 Aug;23(8):474-484
pubmed: 28622076
Front Immunol. 2017 Jun 28;8:760
pubmed: 28702032
Oncoimmunology. 2017 May 11;6(8):e1320630
pubmed: 28919991
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9271-E9279
pubmed: 29078276
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Science. 2018 Mar 30;359(6383):1537-1542
pubmed: 29599246
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Int J Cancer. 1988 Dec 15;42(6):877-82
pubmed: 3192334
Leukemia. 1994 Apr;8(4):652-8
pubmed: 8152260
Blood. 1996 Jun 1;87(11):4913-4
pubmed: 8639869